PITTSBURGH, PA, USA I February 20, 2025 I Myris Therapeuticsâ„¢ emerged from stealth today to announce its strategic focus. Myris, formerly known as ...
New research led by scientists at La Jolla Institute for Immunology (LJI) reveals the workings of a human antibody called mAb 3A6, which may prove to be an important component for Ebola virus ...
By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially resuming development of roxadustat in another indication.
The "Global TROP2 Antibody Market & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering. In what marks a significant leap forward in precision oncology, the TROP2 ...